FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384407811> ?p ?o ?g. }

• W4384407811 abstract "Abstract Background Osteoporosis is a worldwide health issue. Loss of bone mass is a potential risk factor for fragility fractures, and osteoporotic fractures place a considerable burden on society. Bone and muscle represent a functional unit in which the two tissues are intimately interconnected. Ropivacaine is a potent local anesthetic used in clinical practice for intraoperative anesthesia and postoperative pain management, in particular for hip surgery. When injected, Ropivacaine can diffuse locally through, in particular in surrounding skeletal muscle tissue, causing dose-dependent cytotoxicity, oxidative stress and myogenesis impairment. Based on those evidences, we focused our attention on Ropivacaine-induced cytotoxicity on cultured human myoblasts. Methods Primary human myoblasts and myotubes from healthy subjects, osteoarthritic and osteoporotic patients (OP) were cultured in the presence of Ropivacaine. In some experiments, ascorbic acid (AsA) was added as a potent antioxidant agent. Cell viability and ROS levels were evaluated to investigate the myotoxic activity and Real-Time PCR and Western blot analysis carried out to investigate the expression of proliferation and myogenic markers. Results A dose-dependent decrease of cell viability was observed after Ropivacaine exposure in both OP myoblasts and myotubes cultures, whereas those effects were not observed in the presence of Propofol, a general anesthetic. The adding of AsA reduced Ropivacaine negative effects in OP myoblast cultures. In addition, Ropivacaine exposure also increased ROS levels and upregulated Nox4 expression, an enzyme primarily implicated in skeletal muscle ROS generation. AsA treatment counteracted the oxidant activity of Ropivacaine and partially restored the basal condition in cultures. Positive myogenic markers, such as MyoD and Myf5, were downregulated by Ropivacaine exposure, whereas myostatin, a negative regulator of muscle growth and differentiation, was upregulated. The phenotypic deregulation of myogenic controllers in the presence of Ropivacaine was counteracted by AsA treatment. Conclusions Our findings highlight the oxidative stress-mediated myotoxic effect of Ropivacaine on human skeletal muscle tissue cell cultures, and suggest treatment with AsA as valid strategy to mitigate its negative effects and allowing an ameliorated functional skeletal muscle recovery in patients undergoing hip replacement surgery for osteoporotic bone fracture." @default.
• W4384407811 created "2023-07-16" @default.
• W4384407811 creator A5015835259 @default.
• W4384407811 creator A5016115277 @default.
• W4384407811 creator A5027194364 @default.
• W4384407811 creator A5028378902 @default.
• W4384407811 creator A5030642781 @default.
• W4384407811 creator A5034534044 @default.
• W4384407811 creator A5038448337 @default.
• W4384407811 creator A5052695277 @default.
• W4384407811 creator A5062964307 @default.
• W4384407811 creator A5067415258 @default.
• W4384407811 creator A5077140018 @default.
• W4384407811 creator A5085955205 @default.
• W4384407811 date "2023-07-15" @default.
• W4384407811 modified "2023-10-14" @default.
• W4384407811 title "Ascorbic acid reduces Ropivacaine-induced myotoxicity in cultured human osteoporotic skeletal muscle cells" @default.
• W4384407811 cites W1832552668 @default.
• W4384407811 cites W1965538219 @default.
• W4384407811 cites W2001380443 @default.
• W4384407811 cites W2049827972 @default.
• W4384407811 cites W2056903054 @default.
• W4384407811 cites W2075474928 @default.
• W4384407811 cites W2084201504 @default.
• W4384407811 cites W2114795263 @default.
• W4384407811 cites W2136392296 @default.
• W4384407811 cites W2143474482 @default.
• W4384407811 cites W2145362416 @default.
• W4384407811 cites W2159417339 @default.
• W4384407811 cites W2165234958 @default.
• W4384407811 cites W2176651704 @default.
• W4384407811 cites W2225100482 @default.
• W4384407811 cites W2289416150 @default.
• W4384407811 cites W2339521941 @default.
• W4384407811 cites W2501911161 @default.
• W4384407811 cites W2776842400 @default.
• W4384407811 cites W2807732905 @default.
• W4384407811 cites W2913364817 @default.
• W4384407811 cites W2925843715 @default.
• W4384407811 cites W2943932535 @default.
• W4384407811 cites W2944668132 @default.
• W4384407811 cites W4223658150 @default.
• W4384407811 cites W4303184222 @default.
• W4384407811 cites W4310772699 @default.
• W4384407811 cites W4322506548 @default.
• W4384407811 cites W4376865559 @default.
• W4384407811 cites W1803972290 @default.
• W4384407811 doi "https://doi.org/10.1186/s12891-023-06702-5" @default.
• W4384407811 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37454045" @default.
• W4384407811 hasPublicationYear "2023" @default.
• W4384407811 type Work @default.
• W4384407811 citedByCount "0" @default.
• W4384407811 crossrefType "journal-article" @default.
• W4384407811 hasAuthorship W4384407811A5015835259 @default.
• W4384407811 hasAuthorship W4384407811A5016115277 @default.
• W4384407811 hasAuthorship W4384407811A5027194364 @default.
• W4384407811 hasAuthorship W4384407811A5028378902 @default.
• W4384407811 hasAuthorship W4384407811A5030642781 @default.
• W4384407811 hasAuthorship W4384407811A5034534044 @default.
• W4384407811 hasAuthorship W4384407811A5038448337 @default.
• W4384407811 hasAuthorship W4384407811A5052695277 @default.
• W4384407811 hasAuthorship W4384407811A5062964307 @default.
• W4384407811 hasAuthorship W4384407811A5067415258 @default.
• W4384407811 hasAuthorship W4384407811A5077140018 @default.
• W4384407811 hasAuthorship W4384407811A5085955205 @default.
• W4384407811 hasBestOaLocation W43844078111 @default.
• W4384407811 hasConcept C126322002 @default.
• W4384407811 hasConcept C185592680 @default.
• W4384407811 hasConcept C207200792 @default.
• W4384407811 hasConcept C2776151105 @default.
• W4384407811 hasConcept C2779959927 @default.
• W4384407811 hasConcept C2780269707 @default.
• W4384407811 hasConcept C2986274086 @default.
• W4384407811 hasConcept C31903555 @default.
• W4384407811 hasConcept C3763915 @default.
• W4384407811 hasConcept C71924100 @default.
• W4384407811 hasConcept C98274493 @default.
• W4384407811 hasConceptScore W4384407811C126322002 @default.
• W4384407811 hasConceptScore W4384407811C185592680 @default.
• W4384407811 hasConceptScore W4384407811C207200792 @default.
• W4384407811 hasConceptScore W4384407811C2776151105 @default.
• W4384407811 hasConceptScore W4384407811C2779959927 @default.
• W4384407811 hasConceptScore W4384407811C2780269707 @default.
• W4384407811 hasConceptScore W4384407811C2986274086 @default.
• W4384407811 hasConceptScore W4384407811C31903555 @default.
• W4384407811 hasConceptScore W4384407811C3763915 @default.
• W4384407811 hasConceptScore W4384407811C71924100 @default.
• W4384407811 hasConceptScore W4384407811C98274493 @default.
• W4384407811 hasIssue "1" @default.
• W4384407811 hasLocation W43844078111 @default.
• W4384407811 hasLocation W43844078112 @default.
• W4384407811 hasLocation W43844078113 @default.
• W4384407811 hasOpenAccess W4384407811 @default.
• W4384407811 hasPrimaryLocation W43844078111 @default.
• W4384407811 hasRelatedWork W1980279827 @default.
• W4384407811 hasRelatedWork W1996907808 @default.
• W4384407811 hasRelatedWork W2003343206 @default.
• W4384407811 hasRelatedWork W2012593965 @default.
• W4384407811 hasRelatedWork W2016784766 @default.
• W4384407811 hasRelatedWork W2071486154 @default.

• next